# Gritstone Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gritstone-oncology

- Industry: Pharmaceuticals
- Headquarters: Emeryville, US
- Website: www.gritstoneoncology.com
- Total disclosed funding: $195M
- Latest round: Series B (Sep 1, 2017)
- Investors on record: 10

## About

Based in the US, Gritstone Oncology, Inc. is a biotechnology company focused on developing personalized immunotherapies for cancer treatment, targeting specific tumor mutations to enhance the body’s immune response against cancer cells.Gritstone Oncology specializes in creating innovative immunotherapies for cancer treatment. Founded in 2015, the company is headquartered in Emeryville, US. The founders, Andrew Allen, Graham Lord, and Mark Cobbold, have a history of involvement in the biotech sector. Gritstone has successfully raised USD 14.99 mn in its PIPE funding round led by Redmile Group, contributing to a total amount raised of USD 14.99 mn across 10 deals.Gritstone Oncology is primarily focused on developing innovative immunotherapies for cancer treatment. Their core product offering centers around personalized neoantigen therapies, which are designed to harness the body's immune system to target and destroy cancer cells. These therapies aim to provide customized treatment options based on the specific mutations present in an individual’s tumor, thus addressing the unique characteristics of each patient's cancer. Their flagship products include a range of neoantigen-based therapies currently in various stages of clinical development, targeting indications such as non-small cell lung cancer and other solid tumors. Gritstone’s solutions are primarily directed towards oncologists, healthcare providers, and cancer treatment centers across North America and Europe, with an emphasis on markets where advanced cancer therapies are in high demand.Gritstone Oncology reported a revenue of USD 16.34 mn for the year 2023, with an EBITDA of USD -133.32 mn. The company's revenue model is structured around partnerships and collaborations with pharmaceutical companies and healthcare providers, typically involving licensing agreements and joint development programs. Revenue generation is expected to come from the successful commercialization of their immunotherapy products, particularly those with promising results from clinical trials.Gritstone Oncology aims to enhance its product offerings by developing new personalized cancer therapies, though specific launch dates have not been disclosed. The company is also looking to expand its presence in international markets, particularly in Europe and Asia, to meet the growing demand for advanced cancer treatments. The recent funding of USD 14.99 mn will support these initiatives by facilitating further research and development efforts, as well as broadening their market reach. Notably, Casdin Capital, Clarus Ventures, The Column Group, Alexandria Venture Investments, GV, Lilly Asia Ventures, and Trinitas Capital have fully exited their stake in Gritstone Oncology, Inc.

## Funding rounds

- Series B, Sep 1, 2017, $93M — Frazier Healthcare Partners, Versant Ventures, Alexandria Venture Investments, Clarus Ventures, The Column Group, Lilly Asia Ventures, GV, Trinitas Capital
- Series A, Oct 20, 2015, $102M — Frazier Healthcare Partners, Versant Ventures, Clarus Ventures, The Column Group, Redmile Group, Casdin Capital

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series A, Series B
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series A
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- Trinitas Capital (https://capitalatlas.ai/funds/trinitas-capital) — Series B